A large retrospective multicenter study of vaginal melanomas: Implications for new management

Melanoma Research

Volumn 23, Issue 2, 2013, Pages 138-146

  Vaysse, Charlotte ^a   Pautier, Patricia ^b   Filleron, Thomas ^a   Maisongrosse, Veronique ^a   Rodier, Jean François ^c   Lavoue, Vincent ^d   Reyal, Fabien ^e   Thomas, Laurence ^f   De La Fouchardière, Arnaud ^g   Delannes, Martine ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Paul Strauss Centre   (France)

^d Hospital Anne de Bretagne   (France)

^e INSTITUT CURIE   (France)

^f INSTITUT BERGONIÉ   (France)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

conservative surgery; mortality; multicenter study; radiotherapy; targeted therapy; vaginal melanoma

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FOTEMUSTINE; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PELVIS EXENTERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; VAGINAL MELANOMA;

EID: 84874819832     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835e590e     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA-Cancer J Clin 2010; 60:277-300.
2. Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer 1998; 83:1033-1040.
3. Hu DN, Yu GP, McCormick SA. Population-based incidence of vulvar and vaginal melanoma in various races and ethnic groups with comparisons to other site-specific melanomas. Melanoma Res 2010; 20:153-158.
4. Nigogosyan G, Delapava S, Pickren JW. Melanoblasts in vaginal mucosa. Origin for primary malignant melanoma. Cancer 1964; 17:912-913.
5. Bottles K, Lacey CG, Miller TR. Atypical melanocytic hyperplasia of the vagina. Gynecol Oncol 1984; 19:226-230.
6. Kerley SW, Blute ML, Keeney GL. Multifocal malignant melanoma arising in vesicovaginal melanosis. Arch Pathol Lab Med 1991; 115:950-952.
7. Gokaslan H, Sismanoglu A, Pekin T, Kaya H, Ceyhan N. Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 2005; 121:243-248.
8. Gungor T, Altinkaya SO, Ozat M, Bayramoglu H, Mollamahmutoglu L. Primary malignant melanoma of the female genital tract. Taiwan J Obstet Gynecol 2009; 48:169-175.
9. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the literature. Oncologist 2010; 15:772-781.
10. Nakagawa S, Koga K, Kugu K, Tsutsumi O, Taketani Y. The evaluation of the sentinel node successfully conducted in a case of malignant melanoma of the vagina. Gynecol Oncol 2002; 86:387-389.
11. Sugiyama VE, Chan JK, Kapp DS. Management of melanomas of the female genital tract. Curr Opin Oncol 2008; 20:565-569.
12. Bonner JA, Perez-Tamayo C, Reid GC, Roberts JA, Morley GW. The management of vaginal melanoma. Cancer 1988; 62: 2066-2072.
13. Chung AF, Casey MJ, Flannery JT, Woodruff JM, Lewis JL Jr. Malignant melanoma of the vagina report of 19 cases. Obstet Gynecol 1980; 55: 720-727.
14. Reid GC, Schmidt RW, Roberts JA, Hopkins MP, Barrett RJ, Morley GW. Primary melanoma of the vagina: a clinicopathologic analysis. Obstet Gynecol 1989; 74:190-199.
15. Petru E, Nagele F, Czerwenka K, Graf AH, Lax S, Bauer M, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy. Gynecol Oncol 1998; 70:23-26.
16. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010; 116:1358-1365.
17. Konstadoulakis MM, Ricaniadis N, Driscoll DL, Karakousis CP. Malignant melanoma of the female genital system. Eur J Surg Oncol 1994; 20: 141-145.
18. Ragnarsson-Olding B, Johansson H, Rutqvist LE, Ringborg U. Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer 1993; 71:1893-1897.
19. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340-4346.
20. Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008; 99:2065-2069.
21. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. New York: Wiley; 1980.
22. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
23. Cobellis L, Calabrese E, Stefanon B, Raspagliesi F. Malignant melanoma of the vagina. A report of 15 cases. Eur J Gynaecol Oncol 2000; 21: 295-297.
24. Miner TJ, Delgado R, Zeisler J, Busam K, Alektiar K, Barakat R, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004; 11:34-39.
25. Irvin WP Jr, Bliss SA, Rice LW, Taylor PT Jr, Andersen WA. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol 1998; 71:476-480.
26. Takehara M, Saito T, Mizumoto H, Baba T, Tanaka R, Fujimoto T, et al. Imaging studies in patients with malignant melanoma in the female genital tract. Int J Gynecol Cancer 2002; 12:506-509.
27. Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol 2008; 9:973-981.
28. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56:828-834.
29. Kim CJ, Reintgen DS, Balch CM. The new melanoma staging system. Cancer Control 2002; 9:9-15.
30. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
31. Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteenyear disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998; 178:1177-1184.
32. Geisler JP, Look KY, Moore DA, Sutton GP. Pelvic exenteration for malignant melanomas of the vagina or urethra with over 3mm of invasion. Gynecol Oncol 1995; 59:338-341.
33. Benlyazid A, Thariat J, Temam S, Malard O, Florescu C, Choussy O, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010; 136:1219-1225.
34. Coleman RL. Primary vaginal melanoma: a rare and problematic clinical entity. Ann Surg Oncol 2004; 11:4-6.
35. Abramova L, Parekh J, Irvin WPJr, Rice LW, Taylor PT Jr, Anderson WA, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol 2002; 9:840-846.
36. Frumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, et al. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol 2008; 108:478-481.
37. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317.
38. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003; 97:1789-1796.
39. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
40. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
41. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
42. Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther 2009; 9:839-849.
43. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH, et al. c-KIT protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008; 452:27-32.
44. Omholt K, Grafstrom E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17:3933-3942.
45. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011; 17:1684-1691.
46. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C,Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14:6821-6828.
47. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5:737-740.
48. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046-2051.
49. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher JB, et al. KIT is a therapeutic target in metastatic melanoma. JAMA 2011; 22:2327-2334.
50. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J Clin Oncol 2011; 20: 2904-2909.
51. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, et al. Melanoma from bench to bedside: meeting report from the 6th International Melanoma Congress. Pigment Cell Melanoma Res 2010; 23:14-26.
52. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.